Evidence map›Paper›PMID 34063168›Full record

ReviewInternational journal of molecular sciences2021

Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update.

Mayra Colardo, Marco Segatto, Sabrina Di Bartolomeo

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 134 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Advancements in Drug Delivery Systems in Glioblastoma Therapy.International journal of molecular sciences · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Recent advances in molecular mechanisms of microRNAs in pathogenesis and resistance of treatment in glioblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  16. Article
  17. Article
  18. Sialylation Inhibition Impairs Migration and Promotes Adhesion of GBM Cells.International journal of molecular sciences · 2025
    Article
  19. Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mayra ColardoDepartment of Biosciences and Territory, University of Molise, 86090 Pesche, IS, Italy.ORCID 0000-0003-3353-8918
Marco SegattoDepartment of Biosciences and Territory, University of Molise, 86090 Pesche, IS, Italy.ORCID 0000-0003-0465-9470
Sabrina Di BartolomeoDepartment of Biosciences and Territory, University of Molise, 86090 Pesche, IS, Italy.ORCID 0000-0002-5748-1541
University of Molise · IT

Funding

FFABR (Italian Ministry of University and Research) to Sabrina Di Bartolomeo none
6 · The paper itself

Abstract

Gliomas are the most common and challenging malignancies of the central nervous system (CNS), due to their infiltrative nature, tendency to recurrence, and poor response to treatments. Indeed, despite the advances in neurosurgical techniques and in radiation therapy, the modest effects of therapy are still challenging. Moreover, tumor recurrence is associated with the onset of therapy resistance; it is therefore critical to identify effective and well-tolerated pharmacological approaches capable of inducing durable responses in the appropriate patient groups. Molecular alterations of the RTK/PI3K/Akt/mTOR signaling pathway are typical hallmarks of glioma, and several clinical trials targeting one or more players of this axis have been launched, showing disappointing results so far, due to the scarce BBB permeability of certain compounds or to the occurrence of resistance/tolerance mechanisms. However, as RTK/PI3K/mTOR is one of the pivotal pathways regulating cell growth and survival in cancer biology, targeting still remains a strong rationale for developing strategies against gliomas. Future rigorous clinical studies, aimed at addressing the tumor heterogeneity, the interaction with the microenvironment, as well as diverse posology adjustments, are needed-which might unravel the therapeutic efficacy and response prediction of an RTK/PI3K/mTOR-based approach.

Indexed as

Molecular Targeted TherapyAnimalsBrain NeoplasmsGliomaHumansPhosphatidylinositol 3-KinasesReceptor Protein-Tyrosine KinasesSignal TransductionTOR Serine-Threonine KinasesPhosphatidylinositol 3-KinasesReceptor Protein-Tyrosine KinasesTOR Serine-Threonine KinasesEGFRgliomaHCGsPI3K-mTORRTKs

Identifiers

PMID34063168
PMCPMC8124221
OpenAlexW3158045410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.